An Investigation and Analysis of Clinical Trials and Research Centers on Regenerative Medicine Industry: Case comparison between China and other countries

Abstract

The field of stem cells and regenerative medicine is one of the most attractive foci and research hot spots in the current biology and medicine. The international scientific community has made remarkable breakthroughs in the following issues: 1) The basic regulatory theory of stem cells; 2) iPS cells, targeted reprogramming to functional cells and new types of stem cells; 3) Gene edit technologies; 4) Tissue engineering and translational research, drug development using stem cells, nano-materials research and application in regenerative medicine etc. Scientists in institutes and the biology pharmaceutical industry are actively promoting the clinical translation by discovering new mechanisms, innovating technologies and creating new therapies, leading to a big scale market of the regenerative medicine nowadays. Traditional treatments such as drug therapy and surgery often have little effect on such diseases, and fail to meet the growing medical needs of this age-group. Stem cell-based regenerative medicine is expected to become the third treatment option after drug therapy and surgery. With the increasing financial supports and investments in China recent years, a series of important progress have been made to stem cells and regenerative medicine. In this issue, we investigated the stem cell and regenerative medicine industry in the world and china, such as clinical trial and research institutions distribution.